On December 5, 2024, IceCure Medical announced interim results from its ICESECRET study of cryoablation for patients with small renal masses (SRM) who are not candidates for kidney-preserving surgery. The data were presented at the Israeli Urological Association Conference in Eilat, Israel. The study reported an impressive 88.7% recurrence-free rate.
The interim data confirmed that ProSense® cryoablation is highly effective for kidney tumors up to 3 cm in size and a safe procedure for kidney tumors up to 5 cm in patients ineligible for surgery. This highlights the potential of ProSense® to address an unmet medical need in kidney cancer treatment. The positive results provide further clinical validation for the system's application beyond breast cancer.
The efficacy and safety demonstrated in this study are crucial for expanding the adoption of ProSense® in the urology field. These findings support the system's use as a minimally invasive alternative for tumor destruction in a broader range of indications, contributing to IceCure's market diversification strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.